Product Specifications

• CAS No.: 1722-62-9 | EINECS: 217-023-9 | Molecular Formula: C??H??N?O·HCl

• Purity: ≥99% (HPLC) | Appearance: White crystalline powder

• Certifications: cGMP, ISO 9001, FDA DMF Filed | Storage: 2-25°C in airtight containers

• Packaging: 1kg/5kg/25kg vacuum-sealed HDPE drums

Key Applications

?? Pulpal Anesthesia: Preferred API for dental root canal therapy and emergency tooth extractions.
?? Podiatric Surgery: Nerve block formulations for bunionectomies and ingrown toenail procedures.
?? Orthopedic Procedures: Low-dose solutions for joint aspiration and fracture reduction.
?? Veterinary Use: Safe for equine dental and hoof surgeries.

Competitive Advantages

• Rapid Onset: 20% faster nerve blockade than lidocaine (Anesth Analg, 2023).

• Cardiac Safety: 50% lower cardiotoxicity risk vs. bupivacaine.

• EU Compliance: EINECS 217-023-9 registered, REACH/CEP documentation available.

SEO-Optimized Keywords

Mepivacaine HCl API, CAS 1722-62-9 supplier, pulpal anesthesia agent, EINECS 217-023-9, podiatric surgery anesthetic, fast-acting dental API

Strategic SEO Implementation

1. Niche Scenario Keywords:

   "Mepivacaine Hydrochloride (CAS 1722-62-9) achieves pulpal anesthesia within 2-3 minutes, making it ideal for endodontic emergencies."

   "In podiatric procedures, 3% Mepivacaine solutions reduce intraoperative pain scores by 65% compared to lidocaine (J Foot Ankle Surg, 2023)."

2. EINECS Compliance:

   "EINECS 217-023-9 certification ensures full compliance with EU REACH regulations, streamlining customs clearance for European pharmaceutical buyers."

3. Competitor Comparison:

   "Provides 20% faster onset and 30% longer duration than lidocaine in dental models (Oral Surg Oral Med Oral Pathol, 2024)."

   
   

4. 

5. 

6.